BBA
CNTA

Baker Bros. Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Baker Bros. Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6M Hold
670,751
– – 0.15% 45
2025
Q4 		$16.8M Buy
+670,751
New +$17M 0.1% 58
2025
Q2 		– Sell
-1,227,178
Closed -$17.6M – 90
2025
Q1 		$17.6M Hold
1,227,178
– – 0.2% 36
2024
Q4 		$20.6M Hold
1,227,178
– – 0.22% 42
2024
Q3 		$19.6M Buy
1,227,178
+677,966
+123% +$8.31M 0.2% 42
2024
Q2 		$4.96M Buy
+549,212
New +$5.21M 0.06% 65
2022
Q3 		– Sell
-1,127,273
Closed -$5.49M – 118
2022
Q2 		$5.49M Hold
1,127,273
– – 0.03% 79
2022
Q1 		$10.1M Hold
1,127,273
– – 0.06% 67
2021
Q4 		$12.7M Hold
1,127,273
– – 0.06% 71
2021
Q3 		$18.8M Buy
1,127,273
+727,273
+182% +$15.1M 0.08% 65
2021
Q2 		$8.88M Buy
+400,000
New +$9.4M 0.04% 79

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Baker Bros. Advisors's CNTA Position: Q1 2026 in Review

Baker Bros. Advisors held its Centessa Pharmaceuticals (CNTA) position steady in Q1 2026 at 670,751 shares worth $26.6M. The position accounts for 0.15% of the portfolio, ranked #45.

Baker Bros. Advisors first reported a position in CNTA in Q2 2021 and has held it in 11 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Baker Bros. Advisors held 670,751 shares of Centessa Pharmaceuticals worth $26.6M as of Q1 2026.
  • Baker Bros. Advisors left its Centessa Pharmaceuticals share count unchanged in Q1 2026.
  • Centessa Pharmaceuticals made up 0.15% of Baker Bros. Advisors's portfolio in Q1 2026, its #45 holding.
  • Baker Bros. Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.